Company Filing History:
Years Active: 2010-2017
Title: Dirk W Becker: Innovator in Radioisotope Isolation
Introduction
Dirk W Becker is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of radioisotope isolation, holding a total of 3 patents. His work focuses on methods that enhance the production of diagnostic and therapeutic radiopharmaceuticals.
Latest Patents
One of his latest patents is titled "Method and apparatus for isolating the radioisotope molybdenum-99." This innovative method involves vaporizing a source compound containing molybdenum and ionizing it to form ions. The ions are then separated to isolate those containing molybdenum, which can be collected for further use. This process results in molybdenum with a relatively high specific radioactivity, which is essential for producing the diagnostic radioisotope technetium-99m through radioactive decay.
Another significant patent by Becker is "Method and apparatus for isolating a radioisotope." This method also involves vaporizing a source compound containing isotopes of an element. The vaporized compound is ionized to create charged particles, which are then separated to isolate the second isotope. This isolated isotope can be utilized to produce radiopharmaceuticals with enhanced specific activity, improving their therapeutic and diagnostic properties.
Career Highlights
Dirk W Becker is currently associated with Advanced Applied Physics Solutions, Inc. His work at this company emphasizes the development of advanced techniques for isolating radioisotopes, which are crucial in medical applications.
Collaborations
Becker has collaborated with notable colleagues in his field, including Suzanne Lapi and Thomas J Ruth. Their combined expertise contributes to the advancement of radioisotope technology and its applications in medicine.
Conclusion
Dirk W Becker's innovative work in the isolation of radioisotopes has made a significant impact on the field of medical diagnostics and therapeutics. His patents reflect a commitment to enhancing the efficacy of radiopharmaceuticals, ultimately benefiting patient care.